RETRACTED ARTICLE: High-dose therapy and autologous stem cell transplantation for relapsed or high-risk diffuse large B-
- PDF / 608,764 Bytes
- 11 Pages / 595.276 x 790.866 pts Page_size
- 95 Downloads / 176 Views
ORIGINAL ARTICLE
High‑dose therapy and autologous stem cell transplantation for relapsed or high‑risk diffuse large B‑cell lymphoma: a nationwide survey Sung‑Won Kim1 · Yoshitaka Asakura1,2 · Kinuko Tajima1 · Toshiki Iwai3 · Hirofumi Taji4 · Takaaki Chou5 · Yasuo Morishima6,7 · Junji Suzumiya8 · Hisashi Sakamaki9 · Ritsuro Suzuki8,10 · Takahiro Fukuda1 Received: 9 July 2019 / Revised: 28 October 2019 / Accepted: 29 October 2019 © Japanese Society of Hematology 2019
Abstract To investigate the use of high-dose therapy and autologous stem cell transplantation (ASCT) for relapsed or high-risk diffuse large B-cell lymphoma (DLBCL) between 1990 and 2007, we conducted a nationwide survey using the registry database of the Japan Society for Hematopoietic Cell Transplantation. Of the 1222 patients in the database, 576 (47%) received ASCT in first complete remission (CR1), 140 (12%) in first partial remission, 281 (23%) in sensitive relapse, 150 (12%) in resistant or sensitivity-unknown relapse, and 75 (6%) in primary refractory status. With a median follow-up of 22 months, the 2-year overall survival (OS) and progression-free survival rates were 71% and 68%, respectively. The cumulative incidences of 2-year non-relapse mortality and relapse/progression were 6% and 26%, respectively. Relapse/progression after ASCT in the rituximab era (2002–2007) was significantly lower than that in the pre-rituximab era (1990–2001; P
Data Loading...
